Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

19.02.19	Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials (Businesswire)
19.02.19	Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®* (Businesswire)
19.02.19	Gliknik To Receive $15 Mln Payment From Pfizer On Progress With PF-06755347 (RTTNews)
19.02.19	Eli Lilly: Tanezumab 10 Mg Meets Primary Endpoint In Phase 3 Study - Quick Facts (RTTNews)
12.02.19	Merck KGaA And Pfizer : FDA Accepts For Priority Review SBLA For BAVENCIO (RTTNews)
11.02.19	Pfizer: XTANDI Plus Androgen Deprivation Therapy Meets Endpoint In ARCHES Trial (RTTNews)
11.02.19	Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer (Businesswire)
01.02.19	Pfizer Gets Positive CHMP Opinion For Vizimpro 45 Mg (RTTNews)
29.01.19	Pfizer Q4 Results Beat View; But FY19 Outlook Disappoints (RTTNews)
29.01.19	Pfizer Inc. Q4 adjusted earnings Beat Estimates (RTTNews)
29.01.19	PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS (Businesswire)
29.01.19	Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain (RTTNews)
29.01.19	Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain (Businesswire)
15.01.19	First Device For Congenital Heart Defect, AIMT & US Shutdown, ASLN On Watch (RTTNews)
14.01.19	Pfizer Says FDA Accepts Regulatory Submissions For Review Of Tafamidis (RTTNews)
14.01.19	US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy (Businesswire)
07.01.19	Pfizer To Use CytoReason's Machine Learning Model For Drug Discovery (RTTNews)
03.01.19	Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata (Businesswire)
31.12.18	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
27.12.18	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
22.12.18	Merck KGaA & Pfizer Decide To Discontinue JAVELIN Ovarian 100 Study Of Avelumab (RTTNews)
21.12.18	Pfizer Discontinues Phase 2b STRIVE Clinical Trial Due To Futility (RTTNews)
20.12.18	Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis (Businesswire)
20.12.18	Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer (Businesswire)
19.12.18	GSK, Pfizer To Combine Consumer Health Businesses Into New JV - Quick Facts (RTTNews)
19.12.18	Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company (Businesswire)
18.12.18	Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts (Businesswire)
14.12.18	Pfizer Declares First-Quarter 2019 Dividend (Businesswire)
14.12.18	Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab) (Businesswire)
14.12.18	Pfizer Initiates Phase3 Program For 20-Valent Pneumococcal Conjugate Vaccine (RTTNews)
14.12.18	Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older (Businesswire)
11.12.18	Pfizer Posting Notable Loss After Downgrade By J.P. Morgan (RTTNews)
03.12.18	Pfizer Presents Positive Data For PF-05280586, Potential Biosimilar To Rituximab (RTTNews)
02.12.18	Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting (Businesswire)
30.11.18	Pfizer Reaches Global Agreement With AbbVie; To Withdraw Pending Litigation (RTTNews)
30.11.18	Pfizer Reaches a Global Agreement with AbbVie (Businesswire)
27.11.18	Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin) (Businesswire)
21.11.18	U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option (Businesswire)
21.11.18	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
19.11.18	Merck KGaA, Pfizer: JAVELIN Ovarian 200 Trial Did Not Meet Primary Endpoints (RTTNews)
18.11.18	Pfizer Plans To Raise Prices On 41 Drugs In January, Despite Pressure From Trump (RTTNews)
06.11.18	Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration (RTTNews)
02.11.18	U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC (Businesswire)
31.10.18	ViiV Healthcare Announces Positive Phase 3 Results From BRIGHTE Study (RTTNews)
30.10.18	Pfizer Narrows 2018 Revenues Guidance (RTTNews)
30.10.18	Pfizer Inc. Q3 adjusted earnings Beat Estimates (RTTNews)
30.10.18	PFIZER REPORTS THIRD-QUARTER 2018 RESULTS (Businesswire)
29.10.18	ViiV Healthcare Presents Three-year Data For Injectable, Two-drug HIV Regimen (RTTNews)
29.10.18	Biotech Stocks Facing FDA Decision In November (RTTNews)
29.10.18	Pfizer In Clinical Development Deal With Novartis To Advance Treatment Of NASH (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

25.12.24		Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel hätten Anleger an einem Johnson Johnson-Investment von vor 3 Jahren verloren
24.12.24		Börse New York: Dow Jones zeigt sich zum Handelsende fester
24.12.24		Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen
24.12.24		AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück
24.12.24		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
24.12.24		Dienstagshandel in London: Letztendlich Gewinne im FTSE 100
24.12.24		Börse Europa in Grün: STOXX 50 steigt schlussendlich

25.12.24

Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel hätten Anleger an einem Johnson Johnson-Investment von vor 3 Jahren verloren

24.12.24

Börse New York: Dow Jones zeigt sich zum Handelsende fester

24.12.24

Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen

24.12.24

AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück

24.12.24

Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50

24.12.24

Dienstagshandel in London: Letztendlich Gewinne im FTSE 100